AtriCure Reports Q3 Revenue Growth and Projects 2026 Adjusted EBITDA of $91M-$94M
AtriCure (ATRC) reported strong third-quarter financial results, highlighted by a 15% year-over-year increase in worldwide revenue to $154.5 million. The company demonstrated improved profitability during the period, posting a net income of $4 million and an adjusted EBITDA of $27 million. Looking ahead, management has provided optimistic guidance for 2026, projecting adjusted EBITDA to reach between $91 million and $94 million. Additionally, the company is focused on clinical milestones, aiming to complete enrollment for its BoxX-NoAF study by the end of the current year.
Tickers: $ATRC